As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The global generic oncology drugs market size was nearly USD 25 billion in 2020. The market is further expected to grow at a CAGR of 9.1% in the forecast period of 2021-2026 to attain USD 42 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global generic oncology drugs market is being driven by the growing cancer incidences across the globe coupled with rising demand for such drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain.
Region-wise, North America is the leading market for generic oncology drugs accounting for the majority of the global share. The growth of the market in the region can be attributed to the availability of advanced technology and enhanced healthcare infrastructure. On the other hand, the Asia Pacific is expected to be one of the emerging markets owing to the increased government expenditure in the healthcare sector in the region coupled with the presence of increased population.
Generic oncology drugs refer to the drugs that assist in shrinking, controlling, and eliminating the cancer cells present in the human body. They perform a pivotal role in cancer treatment as some of the anti-cancer drugs are only available in the form of generics. Generic oncology drugs share similar active ingredients as the already marketed brand-name cancer care medicine, and they can be characterised by different colours or flavours in comparison to the original drugs. The performance, intended use, quality, dosage form, and route of administration of these drugs are similar to that of their original counterparts.
The EMR report has analysed the major regional markets in the industry, which are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The generic oncology drugs market is driven by the growing prevalence of cancer across the globe, coupled with high costs associated with cancer treatment. These drugs are bioequivalent of and are used as an alternative means to brand-name medicines, providing similar pharmacological effects in cancer treatment. A rapid increase in the number of smokers, coupled with a rise in sedentary and unhealthy lifestyles, has increased the incidences of cancer cases around the world. As a result of this, there has been an acceleration in the demand for cost-effective and viable cancer treatments, including generic oncology drugs. Increasing adulteration in food products and the usage of pesticides in fresh fruits and vegetables has injected a lot of chemicals in the human body responsible for such diseases.
Apart from this, rising government expenditure in the emerging nations to promote generic drugs and reduce healthcare expenses is positively influencing the regional market growth. Furthermore, rapid advancements in the healthcare sector and biotechnology and research field have resulted in early and affordable cancer diagnosis, thus increasing the demand for generic oncology drugs at the prevention stage. Thus, rising geriatric population and growing demand for cost-effective treatment procedures, particularly in emerging regions are aiding the industry further.
Factors such as new product launches and benefits offered by generic drugs are boosting the market. In addition, the growing pharmaceutical industry in developing countries is likely to have a positive impact on the growth of the market in the coming years. The ongoing research and development activities are aiding the market growth. Moreover, the leading players in the market are innovating and launching enhanced products, which is expected to have a positive effect on the industry growth over the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report gives a detailed analysis of the following key players in the global generic oncology drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report||Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Region|
|Breakup by Region||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
|Market Dynamics||SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand|
|Competitive Landscape||Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications|
|Companies Covered||Mylan N.V., Hikma Pharmaceuticals PLC, Stason Pharmaceuticals, Mayne Pharma, Others|
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
7 Industry Opportunities and Challenges
8 Global Generic Oncology Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Generic Oncology Drugs Historical Market (2016-2020)
8.3 Global Generic Oncology Drugs Market Forecast (2021-2026)
8.4 Global Generic Oncology Drugs Market by Region
8.4.1 Market Share
18.104.22.168 North America
22.214.171.124 Asia Pacific
126.96.36.199 Latin America
188.8.131.52 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2016-2020)
9.1.2 Forecast Trend (2021-2026)
9.1.3 Breakup by Country
184.108.40.206 United States of America
9.2.1 Historical Trend (2016-2020)
9.2.2 Forecast Trend (2021-2026)
9.2.3 Breakup by Country
220.127.116.11 United Kingdom
9.3 Asia Pacific
9.3.1 Historical Trend (2016-2020)
9.3.2 Forecast Trend (2021-2026)
9.3.3 Breakup by Country
9.4 Latin America
9.4.1 Historical Trend (2016-2020)
9.4.2 Forecast Trend (2021-2026)
9.4.3 Breakup by Country
9.5 Middle East and Africa
9.5.1 Historical Trend (2016-2020)
9.5.2 Forecast Trend (2021-2026)
9.5.3 Breakup by Country
18.104.22.168 Saudi Arabia
22.214.171.124 United Arab Emirates
126.96.36.199 South Africa
10 Market Dynamics
10.1 SWOT Analysis
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyers Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Project Economics
12.1 Capital Cost of the Project
12.2 Techno-Economic Parameters
12.3 Product Pricing and Margins Across Various Levels of the Supply Chain
12.4 Taxation and Depreciation
12.5 Income Projections
12.6 Expenditure Projections
12.7 Financial Analysis
12.8 Profit Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Company Profiles
13.3.1 Mylan N.V.
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
13.3.2 Hikma Pharmaceuticals PLC
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 Demographic Reach and Achievements
13.3.3 Stason Pharmaceuticals
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
13.3.4 Mayne Pharma
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 Demographic Reach and Achievements
14 Industry Events and Developments
List of Figures and Tables
1. Global Generic Oncology Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global Generic Oncology Drugs Historical Market: Breakup by Region (USD Billion), 2016-2020
3. Global Generic Oncology Drugs Market Forecast: Breakup by Region (USD Billion), 2021-2026
4. North America Generic Oncology Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
5. North America Generic Oncology Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
6. Europe Generic Oncology Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
7. Europe Generic Oncology Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
8. Asia Pacific Generic Oncology Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
9. Asia Pacific Generic Oncology Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
10. Latin America Generic Oncology Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
11. Latin America Generic Oncology Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
12. Middle East and Africa Generic Oncology Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
13. Middle East and Africa Generic Oncology Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
14. Global Generic Oncology Drugs Market Structure
The global generic oncology drugs market reached a value of USD 25 billion in 2020.
The market is projected to grow at a CAGR of nearly 9.1% in the forecast period of 2021-2026.
The market is estimated to reach a value of about USD 42 billion by 2026.
The major drivers of the industry include rising disposable incomes, increasing population, rising cancer incidences, rising demand for these drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain, availability of advanced technology and enhanced healthcare infrastructure.
The increased government expenditure in the healthcare industry is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market, with North America accounting for the largest market share.
The leading players in the market are Mylan N.V., Hikma Pharmaceuticals PLC, Stason Pharmaceuticals, and Mayne Pharma, among others.
The global generic oncology drugs market attained a value of USD 25 billion in 2020, driven by the growth in the healthcare industry. Aided by the rising demand for these drugs to assist patients undergoing chemotherapy, the industry is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 9.1%. The industry is projected to reach USD 42 billion by 2026.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. The major regional markets for generic oncology drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with North America accounting for the largest share of the market. The key players in the above industry include Mylan N.V., Hikma Pharmaceuticals PLC, Stason Pharmaceuticals, and Mayne Pharma, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.